Prevalence in isolates from human, cat and dog swabs of methicillin-susceptible Staphylococcus pseudintermedious (MSSP) and methicillin-resistant S_ pseudintermedius (MRSP) strains, chi-squared test of independence and odds ratio (OR) for the determinants of MRSP
| Variable | MSSP (n (%)1) | MRSP (n (%)1) | OR | 95% OR | P-value |
|---|---|---|---|---|---|
| Species | |||||
| Human | 1 (0.7) | 6 (21.4) | |||
| Cat | 9 (6.6) | 8 (28.6) | 0.15 | 0.01–1.51 | 0.107 |
| Dog | 127 (92.7) | 14 (50.0) | 0.02 | 0.01–0.16 | <0.001 |
| Clinical symptom | |||||
| Conjunctivitis | 20 (14.7) | 7 (35.0) | 3.12 | 1.11–9.78 | 0.025 |
| Inflammation of the ear canal | 23 (16.9) | 3 (15.0) | 0.87 | 0.23–3.20 | 0.830 |
| Rhinitis | 6 (4.4) | 5 (25.0) | 7.22 | 1.96–26.54 | <0.001 |
| Dermatitis/wounds | 37 (27.2) | 6 (30.0) | 1.15 | 0.41–3.21 | 0.794 |
| Other clinical symptoms | 15 (11.0) | 6 (30.0) | 3.46 | 1.15–10.35 | 0.020 |
| Medical history | |||||
| Treatment given to a human2 | 84 (63.2) | 23 (92.0) | 6.71 | 1.52–29.68 | 0.005 |
| Antibiotics2 | 21 (28.0) | 15 (71.4) | 6.43 | 2.20–18.79 | <0.001 |
| Treatment given to the animal 3 | 59 (44.4) | 16 (80.0) | 5.02 | 1.59–15.81 | 0.003 |
| Occupational risk | |||||
| Medical studies4 | 0 (0) | 1 (3.8) | 0.16 | 0.11–0.23 | 0.024 |
| Veterinary studies4 | 4 (3.0) | 4 (15.4) | 5.82 | 1.35–24.99 | 0.009 |
| Origin of animals kept at home | |||||
| Commercial breeder | 13 (92.9) | 7 (53.8) | 0.09 | 0.01–0.90 | 0.021 |
| Adopted from the street | 4 (28.6) | 1 (7.7) | 0.21 | 0.02–2.18 | 0.163 |
| Adopted from another source5 | 1 (7.1) | 6 (46.2) | 11.14 | 1.11–112.01 | 0.021 |
| Factor associated with the animal | |||||
| Cat with outdoor access | 6 (66.7) | 0 (0) | 0.04 | 0.01–0.97 | 0.010 |
Prevalence in isolates from human, cat and dog swabs of methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S_ aureus (MRSA) strains, chi-squared test of independence and odds ratio (OR) for the determinants of MRSA
| Variable | MSSA (n (%)1) | MRSA (n (%)1) | OR | 95% OR | P-value |
|---|---|---|---|---|---|
| Species | |||||
| Human | 1 (0.7) | 6 (21.4) | |||
| Cat | 9 (6.6) | 8 (28.6) | 1.45 | 0.56-3.73 | 0.443 |
| Dog | 127 (92.7) | 14 (50.0) | 1.16 | 0.36–3.75 | 0.806 |
| Medical history | |||||
| Treatment given to a human2 | 65 (48.5) | 16 (50.0) | 1.06 | 0.49–2.30 | 0.879 |
| Antibiotics2 | 35 (27.6) | 12 (41.4) | 1.85 | 0.80–4.28 | 0.143 |
| Factors associated with the animal | |||||
| Antibiotics3 | 40 (42.6) | 5 (17.2) | 0.28 | 0.10–0.80 | 0.013 |
| Cat with outdoor access | 6 (75.0) | 2 (50.0) | 0.33 | 0.03–4.19 | 0.547 |
Frequency of Staphylococcus aureus and S_ pseudintermedius strains by swabbed locationand host species
| Location | Human (n1 = 155) | Cat (n1 = 28) | Dog (n1 = 19) | |
|---|---|---|---|---|
| S. aureus | oral cavity | 47 (30.3%) | 10 (35.7%) | 4 (21.1%) |
| nasal vestibule | 68 (43.8%) | 10 (35.7%) | 7 (36.8%) | |
| conjunctival sac | not applicable | 4 (14.3%) | 2 (10.5%) | |
| ear2 | 24 (15.5%) | 1 (3.6%) | 1 (5.3%) | |
| skin in the elbow flexure | 16 (10.3%) | not applicable | not applicable | |
| skin in the groin | not applicable | 2 (7.1%) | 2 (10.5%) | |
| anus | not applicable | 0 | 1 (5.3%) | |
| wound | not applicable | 1 (3.6%) | 2 (10.5%) | |
| Location | Human (n1 = 7) | Cat (n1 = 17) | Dog (n1 = 141) | |
| S. pseudintermedius | oral cavity | 0 | 3 (17.6%) | 29 (20.6%) |
| nasal vestibule | 3 (42.9%) | 5 (29.4%) | 26 (18.4%) | |
| conjunctival sac | not applicable | 4 (23.5%) | 23 (16.3%) | |
| ear2 | 1 (14.2%) | 2 (11.8%) | 17 (12.1%) | |
| skin in the elbow flexure | 3 (42.9%) | not applicable | not applicable | |
| skin in the groin | not applicable | 2 (11.8%) | 17 (12.1%) | |
| anus | not applicable | 1 (5.9%) | 26 (18.4%) | |
| wound | not applicable | 0 | 3 (2.1%) |
The incidence in isolates from human, cat and dog swabs of Staphylococcus aureus and S_ pseudintermedius strains resistant to selected antimicrobial chemotherapeutics
| Substance | S. aureus (n1 = 202) | S. pseudintermedius (n1 = 165) |
|---|---|---|
| Resistance | Resistance | |
| AMP | 126 (62.4%) | 105 (63.6%) |
| AMC | 57 (28.2%) | 13 (7.9%) |
| PG | 124 (61.4%) | 118 (71.5%) |
| FD | 4 (2.0%) | 1 (0.6%) |
| MUP | 7 (3.5%) | 0 (0%) |
| GM | 1 (0.5%) | 22 (13.3%) |
| CIP | 10 (5.0%) | 18 (10.9%) |
| OX/FOX* | 9 (4.5%) | 20 (12.1%) |
| LZD | 2 (1.0%) | 0 (0%) |
| MAR | 10 (5.0%) | 18 (10.9%) |
| DA | 11 (5.4%) | 68 (41.2%) |
| C | 4 (2.0%) | 39 (23.6%) |
| RD | 3 (1.5%) | 0 (0%) |
| TOB | 1 (0.5%) | 9 (5.5%) |
| E | 59 (29.2%) | 68 (41.2%) |
Frequency distribution of multidrug-resistant (MDR) Staphylococcus aureus strains at the genotypic and phenotypic level by host species
| Analysis level | Species | Not MDR | MDR | P-value2 |
|---|---|---|---|---|
| Genotypic (n1 = 192) | human | 101 (68.2%) | 47 (31.8%) | 0.553 |
| cat | 17 (65.4%) | 9 (34.6%) | ||
| dog | 10 (55.6%) | 8 (44.4%) | ||
| Phenotypic (n1 = 202) | human | 144 (92.9%) | 11 (7.1%) | 0.788 |
| cat | 25 (96.2%) | 1 (3.8%) | ||
| dog | 19 (90.5%) | 2 (9.5%) |
Frequency distribution of multidrug-resistant (MDR) Staphylococcus pseudintermedius strains at the genotypic and phenotypic level by host species
| Analysis level | Species | Not MDR | MDR | P-value1 |
|---|---|---|---|---|
| Genotypic (n = 165) | human | 4 (57.1%) | 3 (42.9%) | 0.025 |
| cat | 3 (17.6%) | 14 (82.4%) | ||
| dog | 73 (51.8%) | 68 (48.2%) | ||
| Phenotypic (n = 165) | human | 4 (57.2%) | 3 (42.8%) | 0.939 |
| cat | 9 (52. 9%) | 8 (47.1%) | ||
| dog | 83 (58.9%) | 58 (41.1%) |
Frequency of occurrence of Staphylococcus aureus and S_ pseudintermedius strains carrying a given resistance gene in isolates from human, cat and dog swabs
| Gene | Carriage rate | |
|---|---|---|
| S. aureus (n1 = 192) | S. pseudintermedius (n1 = 165) | |
| mecA2 | 17 (8.7%) | 24 (14.5%) |
| mecC2 | 8 (4.1%) | 5 (3.0%) |
| blaZ | 153 (79.7%) | 139 (84.2%) |
| tet[L] | 0 (0%) | 8 (4.8%) |
| tet[K] | 14 (7.3%) | 44 (26.7%) |
| tet[O] | 11 (5.7%) | 1 (0.6%) |
| tet[M] | 102 (53.1%) | 88 (53.3%) |
| ermA | 57 (29.7%) | 17 (10.3%) |
| ermB | 44 (22.9%) | 63 (38.2%) |
| ermC | 9 (4.7%) | 10 (6.1%) |
| aac (6′)-Ie-aph(2″)-Ia | 9 (4.7%) | 31 (18.8%) |
| mupA | 0 (0%) | 0 (0%) |
| vanA | 24 (12.5%) | 21 (12.7%) |
| vanB | 6 (3.1%) | 5 (3.0%) |
| fusB2 | 6 (3.1%) | 1 (0.6%) |